Filing summary
Entity and period: The supplied filing is Novelos Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 9, 2012. Although the request identifies Cellectar Biosciences, the registrant named in this filing is Novelos. This is an annual report, not a stand-alone fourth-quarter report.
Business context
Novelos is a development-stage cancer drug company. On April 8, 2011, it acquired Cellectar; the transaction was treated as a reverse acquisition for accounting purposes, with Cellectar as the accounting acquirer. Accordingly, 2010 results represent Cellectar’s historical results, while 2011 includes Cellectar through April 8 and the combined company thereafter, limiting direct year-over-year comparability.
After the acquisition, the company focused on Cellectar’s cancer-targeted pipeline: LIGHT, an iodine-124 PET imaging agent; HOT, an iodine-131 radiotherapeutic; and COLD, a non-radioactive chemotherapy candidate. Development of Novelos’s legacy NOV-002 and NOV-205 programs was suspended.
Financial performance and position
| Metric | FY 2011 / Dec. 31, 2011 | Prior comparable period |
|---|---|---|
| Revenue | No significant revenue from planned operations | No significant revenue from planned operations |
| Research and development expense | $3.599 million | $2.984 million in 2010 |
| General and administrative expense | $2.692 million | $1.157 million in 2010 |
| Merger costs | $746,000 | $53,000 in 2010 |
| Operating loss | $7.038 million | $4.194 million in 2010 |
| Net loss | $7.435 million | $4.560 million in 2010 |
| Basic and diluted loss per share | $0.31 | $0.36 in 2010 |
| Cash used in operating activities | $5.970 million | $3.382 million in 2010 |
| Cash and cash equivalents | $5.506 million | $674,000 at Dec. 31, 2010 |
| Working capital | $5.312 million | Not clearly stated for comparison |
| Total assets | $10.563 million | $4.802 million |
| Total liabilities | $1.082 million | $4.668 million |
| Stockholders’ equity | $9.481 million | $134,000 |
No meaningful operating margin is available because the company had no significant product revenue. The net loss includes non-cash items, including $907,000 of stock-based compensation, $585,000 of depreciation and amortization, and $258,000 of conversion-related interest expense.
Cash rose during 2011 primarily from financing: net proceeds were approximately $4.866 million from the April private placement and $5.298 million from the December offering. The company used $5.970 million in operating cash and spent $118,000 on fixed assets. At year-end, notes payable were $450,000, principally Wisconsin Department of Commerce debt at 2% interest, with payments deferred until 2015; capital lease obligations were about $6,000. Convertible notes and the bank note were settled or converted in connection with the acquisition.
Material changes and outlook
- R&D expense increased 20.6%, mainly from resumed activity, manufacturing, staffing, and other unallocated R&D costs. G&A rose 132.7%, reflecting added personnel, stock compensation, investor relations, and public-company costs.
- Management estimated year-end cash would fund operations into the middle of the third quarter of 2012. Continued operations thereafter depend on additional financing, a strategic transaction, or other funding; the company said it had not entered financing negotiations and gave no assurance funds would be available.
- Management planned, subject to additional funding, to pursue HOT Phase 2 trials in early 2013 and submit a COLD IND in the first quarter of 2013. LIGHT clinical studies were ongoing, with studies in additional solid tumors expected to begin in the second quarter of 2012.
- The independent auditor issued an unqualified opinion on the financial statements but included a going-concern explanatory paragraph, citing recurring losses and substantial doubt about the company’s ability to continue. The company had an accumulated deficit of $31.480 million.
- The April and December financings increased share count and included warrants. At December 31, 2011, 17.404 million warrants and 4.828 million options were outstanding, creating substantial potential dilution relative to 36.908 million shares outstanding.
Risks, contingencies, and unusual items
- All principal pipeline candidates remained in development; clinical efficacy, safety, regulatory approval, manufacturing scale-up, reimbursement, and commercial acceptance were uncertain. Management’s product claims and preclinical findings are not established clinical outcomes.
- A securities class action concerning disclosures about the failed NOV-002 Phase 3 trial remained pending, with a motion to dismiss the second amended complaint under consideration. In the BAM dispute, the court ruled for the company and dismissed counterclaims, but BAM appealed. Management did not expect the litigation contingencies to have a material financial effect, while acknowledging uncertainty.
- The prior NOV-002 Phase 3 trial did not meet its primary or secondary efficacy endpoints; development of NOV-002 for that indication was discontinued. NOV-205’s Phase 2 hepatitis C study showed no viral-load reduction, and its development was suspended.
- The company had no national exchange listing and traded on OTCQX. The filing also cited concentrated ownership, limited trading liquidity, future dilution, and potential stock-price volatility.
- Management reported effective internal control over financial reporting and effective disclosure controls as of December 31, 2011; the auditor did not attest to internal-control effectiveness.
Investor verification priorities
- Confirm current cash runway, subsequent financing, and whether management’s funding-dependent 2012–2013 development plans proceeded.
- Review clinical-trial updates and regulatory status for LIGHT, HOT, and COLD, distinguishing human data from animal or preclinical findings.
- Assess the actual and potential dilution from outstanding warrants, options, and any later equity financings.
- Check developments in the securities class action and BAM appeal, including any change in estimated exposure or insurance coverage.
- Verify the effect of the acquisition-related accounting basis on comparisons with 2010 and subsequent periods.